

Clinical course and costs of care for Crohn's disease: Ma population-based cohort

Gastroenterology

117, 49-57

DOI: [10.1016/s0016-5085\(99\)70549-4](https://doi.org/10.1016/s0016-5085(99)70549-4)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Current pharmacotherapy for inflammatory bowel disease. Expert Opinion on Pharmacotherapy, 1999, 1, 3-14. | 0.9 | 2 |
| 2 | Prevention of Relapse of Crohn's Disease. Inflammatory Bowel Diseases, 2000, 6, 321-328. | 0.9 | 7 |
| 3 | Timing of Surgery for Enterovesical Fistula in Crohn's Disease: Decision Analysis Using a Time-Dependent Compartment Model. Inflammatory Bowel Diseases, 2000, 6, 280-285. | 0.9 | 9 |
| 4 | Therapy for Crohn disease. Current Opinion in Gastroenterology, 2000, 16, 318-323. | 1.0 | 6 |
| 5 | Prevention of relapse of Crohn's disease. Inflammatory Bowel Diseases, 2000, 6, 321-328. | 0.9 | 7 |
| 6 | Review article: the clinical role of anti-TNF α antibody treatment in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2000, 14, 501-514. | 1.9 | 56 |
| 7 | The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease. European Journal of Clinical Pharmacology, 2000, 56, 353-362. | 0.8 | 47 |
| 8 | Analyzing hospital costs for patients with inflammatory bowel disease. American Journal of Gastroenterology, 2000, 95, 577-578. | 0.2 | 2 |
| 9 | Influence of quality of care on quality of life in inflammatory bowel disease (IBD): literature review and studies planned. European Journal of Internal Medicine, 2000, 11, 228-234. | 1.0 | 32 |
| 10 | A review of standard and novel therapies in Crohn's disease. Expert Opinion on Therapeutic Patents, 2000, 10, 1021-1033. | 2.4 | 0 |
| 11 | The Cost of Crohn's Disease. BioDrugs, 2000, 14, 331-344. | 2.2 | 2 |
| 12 | Annual cost of care for Crohn's disease: a payor perspective. American Journal of Gastroenterology, 2000, 95, 1955-1960. | 0.2 | 179 |
| 13 | Azathioprine for maintenance of remission in Crohn's disease: Benefits outweigh the risk of lymphoma. Gastroenterology, 2000, 118, 1018-1024. | 0.6 | 241 |
| 14 | The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology, 2001, 121, 255-260. | 0.6 | 1,125 |
| 15 | Use of anti-tumour necrosis factor agents in inflammatory bowel disease. International Journal of Colorectal Disease, 2001, 16, 1-11. | 1.0 | 52 |
| 16 | Cause of Death in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2001, 7, 250-255. | 0.9 | 66 |
| 17 | Clinical Outcome of Crohn's Disease: Analysis According to the Vienna Classification and Clinical Activity. Inflammatory Bowel Diseases, 2001, 7, 306-313. | 0.9 | 133 |
| 18 | Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study. American Journal of Gastroenterology, 2001, 96, 3348-3355. | 0.2 | 37 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Crohn's Disease: Quality of Life and Costs. <i>Clinics in Colon and Rectal Surgery</i> , 2001, 14, 175-180. | 0.5 | 1 |
| 21 | Research Agenda for Pediatric Gastroenterology, Hepatology and Nutrition: Secretion and Diarrhea: Report of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition for the Children's Digestive Health and Nutrition Foundation. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2002, 35, S246-S249. | 0.9 | 0 |
| 22 | Infliximab Decreases Resource Use Among Patients With Crohn's Disease. <i>Journal of Clinical Gastroenterology</i> , 2002, 35, 151-156. | 1.1 | 106 |
| 23 | Cost of Illness of Crohn's Disease. <i>Pharmacoeconomics</i> , 2002, 20, 639-652. | 1.7 | 73 |
| 24 | Funding the New Biologics – What Can We Learn from Infliximab? The CCOHTA Report: A Gastroenterologist's Viewpoint. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2002, 16, 865-868. | 1.8 | 10 |
| 25 | Funding the New Biologics – CCOHTA Report on the Cost Effectiveness of Infliximab for Crohn's Disease: Pearls and Pitfalls. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2002, 16, 877-879. | 1.8 | 1 |
| 26 | Medical management of inflammatory bowel disease in the new millennium. <i>Comprehensive Therapy</i> , 2002, 28, 39-49. | 0.2 | 3 |
| 30 | The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 51-60. | 1.9 | 403 |
| 31 | The quality of life in patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1603-1609. | 1.9 | 208 |
| 32 | Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2002, 11, 211-218. | 0.9 | 166 |
| 33 | Crohn's disease: step up or top down therapy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2003, 17, 131-137. | 1.0 | 61 |
| 34 | Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 15-21. | 1.9 | 101 |
| 35 | Challenges in IBD Research: Updating the Scientific Agendas. <i>Inflammatory Bowel Diseases</i> , 2003, 9, 137-153. | 0.9 | 18 |
| 36 | Infliximab Treatment of Rheumatoid Arthritis and Crohn's Disease. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1256-1265. | 0.9 | 86 |
| 37 | Burden of illness of Crohn's disease in Spain. <i>Digestive and Liver Disease</i> , 2003, 35, 853-861. | 0.4 | 70 |
| 38 | Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. <i>Gastroenterology</i> , 2003, 125, 320-327. | 0.6 | 306 |
| 39 | Considerations in the management of steroid-dependent Crohn's disease. <i>Gastroenterology</i> , 2003, 125, 906-910. | 0.6 | 13 |
| 40 | RDP58, a Novel Immunomodulatory Peptide with Anti-Inflammatory Effects. A Pharmacological Study in Trinitrobenzene Sulphonic Acid Colitis and Crohn Disease. <i>Scandinavian Journal of Gastroenterology</i> , 2003, 38, 526-532. | 0.6 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 41 | Insurance problems among inflammatory bowel disease patients: results of a Dutch population based study. <i>Gut</i> , 2003, 52, 358-362. | 6.1 | 15 |
| 42 | Risk of Early Surgery for Crohn's Disease: Implications for Early Treatment Strategies. <i>American Journal of Gastroenterology</i> , 2003, 98, 2712-2718. | 0.2 | 124 |
| 44 | Evaluation of a stochastic Markov-chain model for the development of forelimb injuries in Thoroughbred racehorses. <i>American Journal of Veterinary Research</i> , 2003, 64, 328-337. | 0.3 | 17 |
| 45 | Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. <i>Gut</i> , 2004, 53, 1471-1478. | 6.1 | 269 |
| 46 | Utilization of Health Care Resources by Individuals with Inflammatory Bowel Disease in the United States: A Profile of Time Since Diagnosis. <i>American Journal of Gastroenterology</i> , 2004, 99, 650-655. | 0.2 | 59 |
| 47 | Cost of outpatient care in patients with inflammatory bowel disease in a German University Hospital. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 192-199. | 1.4 | 42 |
| 48 | Aminosalicylates in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 60-65. | 1.9 | 52 |
| 49 | Has disease outcome in Crohn's disease changed during the last four decades?. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 483-496. | 1.9 | 103 |
| 50 | Smoking and Immunomodulators do not Influence the Response or Duration of Response to Infliximab in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 346-351. | 0.9 | 47 |
| 51 | The Role of Quality of Care in Health-related Quality of Life in Patients with IBD. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 392-398. | 0.9 | 59 |
| 52 | Crohn's Is Not a 6-Week Disease. <i>Inflammatory Bowel Diseases</i> , 2004, 10, S2-S10. | 0.9 | 30 |
| 53 | Jejunoleal Crohn's disease: a case-control study. <i>Gastroenterologie Clinique Et Biologique</i> , 2004, 28, 160-166. | 0.9 | 8 |
| 54 | Crohn's disease over 20 years after diagnosis in a referral population. <i>Gastroenterologie Clinique Et Biologique</i> , 2004, 28, 1233-1239. | 0.9 | 27 |
| 55 | Chimio-prévention du cancer colorectal dans les maladies inflammatoires intestinales chroniques. Quels sont les médicaments proposés ?. <i>Acta Endoscopica</i> , 2004, 34, 199-213. | 0.0 | 0 |
| 56 | Gastroesophageal reflux disease: Could intervention in childhood reduce the risk of later complications?. <i>The American Journal of Medicine: Supplement</i> , 2004, 117, 23-29. | 1.7 | 23 |
| 58 | Crohn's disease patients who quit smoking have a reduced risk of reoperation for recurrence. <i>American Journal of Surgery</i> , 2004, 187, 219-225. | 0.9 | 121 |
| 59 | Management for severe Crohn's disease: A lifetime cost-utility analysis. <i>International Journal of Technology Assessment in Health Care</i> , 2004, 20, 274-279. | 0.2 | 54 |
| 60 | Infliximab use in Crohn's disease: impact on health care resources in the UK. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 1047-1052. | 0.8 | 61 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 63 | The Case for Using 5-Aminosalicylates in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 609-612. | 0.9 | 16 |
| 64 | Clinical features and complications of Crohn's disease. , 2003, , 291-304. | | 1 |
| 65 | Pharmacoeconomics and inflammatory bowel disease. , 2003, , 471-480. | | 0 |
| 66 | Budesonide for Maintenance of Remission in Patients with Crohn's Disease in Medically Induced Remission: A Predetermined Pooled Analysis of Four Randomized, Double-Blind, Placebo-Controlled Trials. <i>American Journal of Gastroenterology</i> , 2005, 100, 1780-1787. | 0.2 | 124 |
| 67 | Epidemiology and Precaution 150 Years Before Snow. <i>Epidemiology</i> , 2005, 16, 271-272. | 1.2 | 1 |
| 68 | Estimating Rare Disease Prevalence From Administrative Hospitalization Databases. <i>Epidemiology</i> , 2005, 16, 270-271. | 1.2 | 15 |
| 69 | Isolated Ileal Erosions in Patients With Mildly Altered Bowel Habits A Follow-up Study of 28 Patients. <i>American Journal of Clinical Pathology</i> , 2005, 125, 838-846. | 0.4 | 9 |
| 70 | The costs of human <i>Campylobacter</i> infections and sequelae in the Netherlands: A DALY and cost-of-illness approach. <i>Acta Agriculturae Scandinavica Section C: Food Economics</i> , 2005, 2, 35-51. | 0.1 | 22 |
| 71 | Economic Implications of Biological Therapies for Crohn's Disease. <i>Pharmacoeconomics</i> , 2005, 23, 875-888. | 1.7 | 26 |
| 72 | Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. <i>Gastroenterology</i> , 2005, 128, 862-869. | 0.6 | 548 |
| 73 | Early or late guided missile in the treatment of Crohn's disease?. <i>Digestive and Liver Disease</i> , 2005, 37, 973-979. | 0.4 | 13 |
| 74 | Economics of the Use of Biologics in the Treatment of Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2006, 35, 867-882. | 1.0 | 28 |
| 75 | Risks and Benefits of Infliximab for the Treatment of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1017-1024. | 2.4 | 130 |
| 76 | Pharmacoeconomic Analyses of Azathioprine, Methotrexate and Prospective Pharmacogenetic Testing for the Management of Inflammatory Bowel Disease. <i>Pharmacoeconomics</i> , 2006, 24, 767-781. | 1.7 | 83 |
| 77 | Health Care Resource Utilization in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 731-743. | 2.4 | 75 |
| 78 | Step-Up Versus Top-Down: Application of New Biological Agents in Pediatric Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1094-1096. | 2.4 | 6 |
| 79 | Cost Analysis and Cost Determinants in a European Inflammatory Bowel Disease Inception Cohort With 10 Years of Follow-up Evaluation. <i>Gastroenterology</i> , 2006, 131, 719-728. | 0.6 | 213 |
| 80 | Biological Therapy in the Management of Recent-Onset Crohn's Disease. <i>Drugs</i> , 2006, 66, 1431-1439. | 4.9 | 29 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 81 | Economic burden of inflammatory bowel disease: a UK perspective. Expert Review of Pharmacoeconomics and Outcomes Research, 2006, 6, 471-482. | 0.7 | 27 |
| 82 | Disease outcome of inflammatory bowel disease patients: General outline of a Europe-wide population-based 10-year clinical follow-up study. Scandinavian Journal of Gastroenterology, 2006, 41, 46-54. | 0.6 | 71 |
| 83 | Conventional therapy for Crohn's disease. World Journal of Gastroenterology, 2006, 12, 4794. | 1.4 | 16 |
| 84 | Factors associated with disease evolution in Greek patients with inflammatory bowel disease. BMC Gastroenterology, 2006, 6, 21. | 0.8 | 23 |
| 85 | Review article: should we treat symptoms or lesions in Crohn's disease? The case for treating symptoms. Alimentary Pharmacology and Therapeutics, 2006, 24, 33-36. | 1.9 | 45 |
| 86 | Review article: altering the natural history of Crohn's disease ? evidence for and against current therapies. Alimentary Pharmacology and Therapeutics, 2006, 25, 061016063002002-??? | 1.9 | 101 |
| 87 | Inflammatory Bowel Disease: Pandora's Box, Present and Future. Annals of the New York Academy of Sciences, 2006, 1072, 365-378. | 1.8 | 17 |
| 88 | Isolated Ileal Erosions in Patients With Mildly Altered Bowel Habits. American Journal of Clinical Pathology, 2006, 125, 838-846. | 0.4 | 54 |
| 89 | Hospitalization, Surgery, and Readmission Rates of IBD in Canada: A Population-Based Study. American Journal of Gastroenterology, 2006, 101, 110-118. | 0.2 | 144 |
| 90 | Utilization of Health-Care Resources by Patients With IBD in Manitoba: A Profile of Time Since Diagnosis. American Journal of Gastroenterology, 2007, 102, 1683-1691. | 0.2 | 36 |
| 91 | Treatment inferred disease severity in Crohn's disease: Evidence for a European gradient of disease course. Scandinavian Journal of Gastroenterology, 2007, 42, 333-344. | 0.6 | 22 |
| 92 | Medical Therapy for Crohn's Disease: Top-Down or Step-Up?. Digestive Diseases, 2007, 25, 260-266. | 0.8 | 36 |
| 93 | Medical Management of Crohn's Disease. Clinics in Colon and Rectal Surgery, 2007, 20, 269-281. | 0.5 | 13 |
| 94 | Fibrogenesis in Crohn's Disease. American Journal of Gastroenterology, 2007, 102, 439-448. | 0.2 | 244 |
| 95 | Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies. Expert Review of Gastroenterology and Hepatology, 2007, 1, 101-112. | 1.4 | 5 |
| 96 | Biological therapies in inflammatory bowel disease: top-down or bottom-up?. Current Opinion in Gastroenterology, 2007, 23, 395-399. | 1.0 | 46 |
| 97 | Health-Related Quality of Life During Natalizumab Maintenance Therapy for Crohn's Disease. American Journal of Gastroenterology, 2007, 102, 2737-2746. | 0.2 | 48 |
| 98 | Risk for Active Tuberculosis in Inflammatory Bowel Disease Patients. Clinical Gastroenterology and Hepatology, 2007, 5, 1070-1075.e1. | 2.4 | 59 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 117 | Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. <i>Clinical Therapeutics</i> , 2008, 30, 393-404. | 1.1 | 145 |
| 118 | How often and for how long are IBD patients expected to be sick, off work, or in hospital each year?. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S48-S49. | 0.9 | 2 |
| 120 | How expensive is inflammatory bowel disease? A critical analysis. <i>World Journal of Gastroenterology</i> , 2008, 14, 6641. | 1.4 | 57 |
| 121 | Infliximab: A Review of its Use in the Treatment of Crohn's Disease. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2250. | 0.1 | 0 |
| 122 | Adverse Events Associated With Common Therapy Regimens for Moderate-to-Severe Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2009, 104, 2524-2533. | 0.2 | 188 |
| 123 | Appropriateness of colonoscopy in Europe (EPAGE II) – Chronic diarrhea and known inflammatory bowel disease. <i>Endoscopy</i> , 2009, 41, 218-226. | 1.0 | 27 |
| 124 | Crohn's disease in a southern European country: Montreal classification and clinical activity. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1343-1350. | 0.9 | 22 |
| 125 | Resource use and societal costs for Crohn's disease in Sweden. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1882-1890. | 0.9 | 31 |
| 126 | Intestinal Surgery for Crohn's Disease: Predictors of Recovery, Quality of Life, and Costs. <i>Journal of Gastrointestinal Surgery</i> , 2009, 13, 2128-2135. | 0.9 | 23 |
| 127 | Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 265-274. | 1.9 | 111 |
| 128 | Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn's disease patients by Markov analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 735-744. | 1.9 | 19 |
| 129 | Intestinal fibrosis in IBD – a dynamic, multifactorial process. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 228-235. | 8.2 | 271 |
| 130 | Clinical course of Crohn's disease first diagnosed at surgery for acute abdomen. <i>Digestive and Liver Disease</i> , 2009, 41, 269-276. | 0.4 | 45 |
| 131 | Effective dilation of small-bowel strictures by double-balloon enteroscopy in patients with symptomatic Crohn's disease (with video). <i>Gastrointestinal Endoscopy</i> , 2009, 70, 1030-1036. | 0.5 | 121 |
| 132 | Treatment of even mild to moderate Crohn's disease is a long-term challenge due to its remitting and relapsing course. <i>Drugs and Therapy Perspectives</i> , 2009, 25, 10-12. | 0.3 | 0 |
| 133 | Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn's Disease. <i>Pharmacoeconomics</i> , 2009, 27, 609-621. | 1.7 | 40 |
| 134 | Management of Crohn's Disease in Adults. <i>American Journal of Gastroenterology</i> , 2009, 104, 465-483. | 0.2 | 883 |
| 135 | Safety Profile of IBD Therapeutics: Infectious Risks. <i>Gastroenterology Clinics of North America</i> , 2009, 38, 691-709. | 1.0 | 36 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 136 | Evolving Inflammatory Bowel Disease Treatment Paradigms: Top-Down Versus Step-Up. <i>Gastroenterology Clinics of North America</i> , 2009, 38, 577-594. | 1.0 | 22 |
| 137 | Prevalence and Outcome of Anemia After Restorative Proctocolectomy. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 726-739. | 0.7 | 32 |
| 138 | Infliximab Maintenance Therapy Is Associated With Decreases in Direct Resource Use in Patients With Luminal or Fistulizing Crohn's Disease. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 950-956. | 1.1 | 20 |
| 139 | Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 1302-1309. | 0.8 | 32 |
| 140 | Fibrosis in the GI Tract: Pathophysiology, Diagnosis and Treatment Options. <i>Frontiers of Gastrointestinal Research</i> , 2009, , 15-31. | 0.1 | 5 |
| 141 | Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 779-786. | 0.8 | 13 |
| 142 | Scheduled Maintenance Therapy with Infliximab Improves the Prognosis of Crohn's Disease: A Single Center Prospective Cohort Study in Japan. <i>Tohoku Journal of Experimental Medicine</i> , 2010, 220, 207-215. | 0.5 | 2 |
| 143 | Validation of the Spanish version of a questionnaire to measure quality of care through the eyes of patients with inflammatory bowel disease (QUOTE-IBD). <i>Inflammatory Bowel Diseases</i> , 2010, 16, 982-992. | 0.9 | 14 |
| 144 | Adalimumab for Crohn's disease in clinical practice at Mayo clinic: The first 118 patients. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1912-1921. | 0.9 | 45 |
| 145 | Adverse effects of biologics used for treating IBD. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 167-182. | 1.0 | 175 |
| 146 | Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1276-1285. | 1.9 | 42 |
| 147 | A claims-based Markov model for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 448-458. | 1.9 | 18 |
| 148 | Adverse clinical phenotype in inflammatory bowel disease: A cross sectional study identifying factors potentially amenable to change. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1250-1258. | 1.4 | 33 |
| 150 | A Maximum Likelihood Estimator of a Markov Model for Disease Activity in Crohn's Disease and Ulcerative Colitis for Annually Aggregated Partial Observations. <i>Medical Decision Making</i> , 2010, 30, 132-142. | 1.2 | 8 |
| 151 | The pharmacoeconomics of biologic therapy for IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 103-109. | 8.2 | 24 |
| 153 | Recurrence and Impact of Postoperative Prophylaxis in Laparoscopically Treated Primary Ileocolic Crohn Disease. <i>Archives of Surgery</i> , 2010, 145, 42-7. | 2.3 | 25 |
| 154 | What is the optimal therapy for Crohn's disease: step-up or top-down?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 167-180. | 1.4 | 36 |
| 155 | Evolving Inflammatory Bowel Disease Treatment Paradigms: Top-Down Versus Step-Up. <i>Medical Clinics of North America</i> , 2010, 94, 1-18. | 1.1 | 33 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 156 | Clinical practice in Crohn's disease in bordering regions of two countries: Different medical options, distinct surgical events. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 301-311. | 0.6 | 6 |
| 157 | 5-Aminosalicylic acid dependency in Crohn's disease: A Danish Crohn Colitis Database study. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 575-581. | 0.6 | 23 |
| 158 | PGI26 CANADIAN COST-UTILITY ANALYSIS OF INITIATION AND MAINTENANCE TREATMENT WITH ANTI-TNF DRUGS FOR REFRACTORY CROHN'S DISEASE. <i>Value in Health</i> , 2010, 13, A73. | 0.1 | 0 |
| 159 | Safety Profile of IBD Therapeutics: Infectious Risks. <i>Medical Clinics of North America</i> , 2010, 94, 115-133. | 1.1 | 18 |
| 160 | The potential for disease modification in Crohn's disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 79-85. | 8.2 | 80 |
| 161 | The Natural History of Adult Crohn's Disease in Population-Based Cohorts. <i>American Journal of Gastroenterology</i> , 2010, 105, 289-297. | 0.2 | 810 |
| 162 | Strategies for the Prevention of Postoperative Recurrence in Crohn's Disease: Results of a Decision Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 2009-2017. | 0.2 | 44 |
| 163 | A framework for evidence-based health care incentives simulation. , 2011, , . | | 1 |
| 164 | In favour of early surgery in Crohn's disease: A hypothesis to be tested. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 1-4. | 0.6 | 27 |
| 165 | Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 301-316. | 0.6 | 33 |
| 166 | Cost Effectiveness of Treatments for Inflammatory Bowel Disease. <i>Pharmacoeconomics</i> , 2011, 29, 387-401. | 1.7 | 34 |
| 167 | Current perspectives on <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> , <i>Johne</i> 's disease, and Crohn's disease: a Review. <i>Critical Reviews in Microbiology</i> , 2011, 37, 141-156. | 2.7 | 72 |
| 169 | CCR3 Blockade Attenuates Eosinophilic Ileitis and Associated Remodeling. <i>American Journal of Pathology</i> , 2011, 179, 2302-2314. | 1.9 | 38 |
| 170 | Markov model projection of remission status for early vs. delayed step-up adalimumab use in moderate to severe Crohn's disease.. <i>Inflammatory Bowel Diseases</i> , 2011, 17, S52-S53. | 0.9 | 0 |
| 171 | Treatment costs for the group of patients with non-specific inflammatory bowel disease during acute exacerbation and further annual observation. <i>Przegląd Gastroenterologiczny</i> , 2011, 1, 36-44. | 0.3 | 1 |
| 172 | Markov model projection of remission status for early versus delayed step-up adalimumab use in moderate to severe crohn's disease. <i>Gut</i> , 2011, 60, A137-A137. | 6.1 | 1 |
| 173 | Systematic review: the role of tacrolimus in the management of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1282-1294. | 1.9 | 53 |
| 174 | Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 838-848. | 0.9 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 175 | Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1603-1609. | 0.9 | 110 |
| 177 | Practical application of anti-TNF therapy for luminal Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 2366-2391. | 0.9 | 18 |
| 179 | Current and future role of biomarkers in Crohn's disease risk assessment and treatment. <i>Clinical and Experimental Gastroenterology</i> , 2011, 4, 127. | 1.0 | 16 |
| 180 | Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. <i>Gut</i> , 2011, 60, 1754-1763. | 6.1 | 110 |
| 181 | Factors affecting outcomes in Crohn's disease over 15 years. <i>Gut</i> , 2012, 61, 1140-1145. | 6.1 | 108 |
| 183 | Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn's Disease. <i>Clinical Medicine Insights Gastroenterology</i> , 2012, 5, CGast.S7613. | 1.0 | 2 |
| 184 | Hospitalisations and surgery in Crohn's disease. <i>Gut</i> , 2012, 61, 622-629. | 6.1 | 244 |
| 185 | New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. <i>Gut</i> , 2012, 61, i36-i46. | 6.1 | 168 |
| 187 | Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF drugs for refractory Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 77-85. | 0.6 | 29 |
| 188 | Inflammatory Bowel Disease: A Canadian Burden of Illness Review. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012, 26, 811-817. | 1.8 | 229 |
| 189 | Burden of Crohn's disease: economics and quality of life aspects in Italy. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 209. | 0.7 | 13 |
| 190 | Direct Medical Cost of Managing IBD Patients: A Canadian Population-based Study. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1498-1508. | 0.9 | 71 |
| 191 | Cost-Utility Analysis of Biologic Treatments for Moderate to Severe Crohn's Disease. <i>Pharmacotherapy</i> , 2012, 32, 515-526. | 1.2 | 27 |
| 192 | ¹⁸ F-FDG positron emission tomography: potential utility in the assessment of Crohn's disease. <i>Abdominal Imaging</i> , 2012, 37, 377-386. | 2.0 | 18 |
| 193 | Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn's Disease: Results of a Decision Analysis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 472-480. | 1.1 | 18 |
| 194 | Predictive factors for an uncomplicated long-term course of Crohn's disease: A retrospective analysis. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e263-e270. | 0.6 | 27 |
| 195 | Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease. <i>European Journal of Health Economics</i> , 2013, 14, 853-861. | 1.4 | 40 |
| 196 | Health Care Costs of Complex Perianal Fistula in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3400-3406. | 1.1 | 38 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 197 | A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 654-666. | 2.4 | 168 |
| 198 | Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 438-444. | 1.9 | 37 |
| 199 | Inflammatory Bowel Disease: An Expanding Global Health Problem. <i>Clinical Medicine Insights Gastroenterology</i> , 2013, 6, CGast.S12731. | 1.0 | 237 |
| 200 | Cost-effectiveness of Nonmelanoma Skin Cancer Screening in Crohn's Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2787-2795. | 0.9 | 9 |
| 201 | Biological therapies in Crohn's disease: are they cost-effective? A critical appraisal of model-based analyses. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 815-824. | 0.7 | 39 |
| 202 | Impact of balloon-assisted enteroscopy on the diagnosis and management of suspected and established small-bowel Crohn's disease. <i>Endoscopy International Open</i> , 2014, 02, E201-E206. | 0.9 | 20 |
| 203 | Description and prediction of the development of metabolic syndrome in Dongying City: a longitudinal analysis using the Markov model. <i>BMC Public Health</i> , 2014, 14, 1033. | 1.2 | 14 |
| 204 | The Impact of Moderate-to-severe Crohn's Disease on Employees' Salary Growth. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1734-1738. | 0.9 | 4 |
| 205 | Effect of Aging on Healthcare Costs of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 637-645. | 0.9 | 15 |
| 206 | Understanding Proximal-Distal Economic Projections of the Benefits of Childhood Preventive Interventions. <i>Prevention Science</i> , 2014, 15, 807-817. | 1.5 | 4 |
| 207 | Challenges in Designing a National Surveillance Program for Inflammatory Bowel Disease in the United States. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 398-415. | 0.9 | 33 |
| 208 | When and How to Stop Anti-TNF Treatment in Inflammatory Bowel Disease: Predictors of Relapse after Stopping Treatment. <i>Frontiers of Gastrointestinal Research</i> , 0, , 224-228. | 0.1 | 0 |
| 209 | Predictors of ICU Admission and Outcomes 1 Year Post-Admission in Persons with IBD. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1. | 0.9 | 4 |
| 210 | Economic implications of biological therapy for Crohn's disease. <i>Przegląd Gastroenterologiczny</i> , 2015, 4, 197-202. | 0.3 | 2 |
| 211 | Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database. <i>Current Medical Research and Opinion</i> , 2015, 31, 1655-1664. | 0.9 | 31 |
| 212 | Health Care Cost Analysis in a Population-based Inception Cohort of Inflammatory Bowel Disease Patients in the First Year of Diagnosis. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 988-996. | 0.6 | 40 |
| 213 | The epidemiology of inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 942-951. | 0.6 | 272 |
| 214 | Homocysteine Promotes Intestinal Fibrosis in Rats with Trinitrobenzene Sulfonic Acid-Induced Colitis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 375-381. | 1.1 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 215 | Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception Cohort. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 747-753. | 0.6 | 38 |
| 217 | Higher Levels of Knowledge Reduce Health Care Costs in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 615-622. | 0.9 | 53 |
| 218 | Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 121-131. | 0.9 | 47 |
| 219 | Medical Therapy of Fibrostenotic Crohn's Disease. <i>Visceral Medicine</i> , 2015, 31, 259-264. | 0.5 | 2 |
| 220 | Precision-cut rat, mouse, and human intestinal slices as novel models for the early-onset of intestinal fibrosis. <i>Physiological Reports</i> , 2015, 3, e12323. | 0.7 | 19 |
| 221 | Cost-effectiveness of Prophylaxis Against <i>Pneumocystis jiroveci</i> Pneumonia in Patients with Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3743-3755. | 1.1 | 14 |
| 222 | Costs in inflammatory bowel diseases. <i>Przegląd Gastroenterologiczny</i> , 2016, 1, 6-13. | 0.3 | 22 |
| 223 | Demographic and Clinical Predictors of High Healthcare Use in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1442-1449. | 0.9 | 72 |
| 224 | Clinical predictors of Crohn's disease course. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1122-1125. | 0.8 | 11 |
| 225 | Group-Based Trajectory Modeling of Healthcare Financial Charges in Inflammatory Bowel Disease: A Comprehensive Phenotype. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e181. | 1.3 | 14 |
| 226 | Costs of Crohn's Disease According to Severity States in France. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2924-2932. | 0.9 | 6 |
| 227 | Rates and Reasons for Nonuse of Prescription Medication for Inflammatory Bowel Disease in a Referral Clinic. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 919-924. | 0.9 | 11 |
| 228 | Inflammatory Bowel Disease Patients' Participation, Attitude and Preferences Toward Exercise. <i>International Journal of Sports Medicine</i> , 2016, 37, 665-670. | 0.8 | 6 |
| 229 | Course of Crohn's Disease. , 2016, , 31-42. | | 0 |
| 230 | Consensus statements on Crohn's disease. Part 2: Management. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 56-68. | 1.4 | 42 |
| 231 | Top-down approach to biological therapy of Crohn's disease. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 285-293. | 1.4 | 11 |
| 232 | Evaluation of Health Economics in Inflammatory Bowel Disease. , 2017, , 291-297. | | 0 |
| 233 | The Natural History of Inflammatory Bowel Disease. , 2017, , 301-309. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 253 | Physiciansâ€™ Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohnâ€™s Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2555-2563. | 1.1 | 12 |
| 254 | Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohnâ€™s Disease. <i>Pharmacoeconomics</i> , 2019, 37, 1509-1523. | 1.7 | 7 |
| 255 | Herbs-Partitioned Moxibustion Combined with Acupuncture Inhibits TGF- β 1-Smad-Snail-Induced Intestinal Epithelial Mesenchymal Transition in Crohnâ€™s Disease Model Rats. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-9. | 0.5 | 7 |
| 256 | The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohnâ€™s Disease in the Biosimilar Era. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 369-379. | 0.9 | 7 |
| 257 | Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1462-1473. | 0.9 | 15 |
| 258 | Predictive factors for exacerbation and re-exacerbation in chronic obstructive pulmonary disease: an extension of the Cox model to analyze data from the Swiss COPD cohort. <i>Multidisciplinary Respiratory Medicine</i> , 2019, 14, 7. | 0.6 | 11 |
| 259 | Assessment of Patientsâ€™ Future Outlook after Bowel Resection in Crohnâ€™s Disease. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-7. | 0.7 | 1 |
| 260 | Pathogenesis of fibrostenosing Crohn's disease. <i>Translational Research</i> , 2019, 209, 39-54. | 2.2 | 60 |
| 261 | Simulating the Risk of Stroke in China Using Markov Model Based on National Screening Data. , 2019, , . | | 2 |
| 262 | A novel surgical predictive model for Chinese Crohn's disease patients. <i>Medicine (United States)</i> , 2019, 98, e17510. | 0.4 | 16 |
| 263 | Intestinal fibrosis. <i>Molecular Aspects of Medicine</i> , 2019, 65, 100-109. | 2.7 | 77 |
| 264 | Developing a core outcome set for fistulising perianal Crohnâ€™s disease. <i>Gut</i> , 2019, 68, 226-238. | 6.1 | 64 |
| 265 | Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohnâ€™s Disease: A Cost-Effectiveness Analysis in a Simulated Cohort. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 103-111. | 0.9 | 34 |
| 266 | Lifetime Economic Burden of Crohnâ€™s Disease and Ulcerative Colitis by Age at Diagnosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 889-897.e10. | 2.4 | 53 |
| 268 | Meta-analysis of early bowel resection versus initial medical therapy in patient's with ileocolonic Crohn's disease. <i>International Journal of Colorectal Disease</i> , 2020, 35, 501-512. | 1.0 | 4 |
| 269 | Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohnâ€™s disease using real world evidence in Thailand. <i>Journal of Medical Economics</i> , 2020, 23, 1302-1310. | 1.0 | 3 |
| 270 | Betulinic acid hydroxamate prevents colonic inflammation and fibrosis in murine models of inflammatory bowel disease. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1124-1138. | 2.8 | 21 |
| 271 | Role of non-inflammatory factors in intestinal fibrosis. <i>Journal of Digestive Diseases</i> , 2020, 21, 315-318. | 0.7 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 272 | Decrease in primary but not in secondary abdominal surgery for Crohn's disease: nationwide cohort study, 1990-2014. <i>British Journal of Surgery</i> , 2020, 107, 1529-1538. | 0.1 | 38 |
| 273 | Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. <i>Gut</i> , 2020, 69, 658-664. | 6.1 | 21 |
| 274 | Strictureplasty versus bowel resection for the surgical management of fibrostenotic Crohn's disease: a systematic review and meta-analysis. <i>International Journal of Colorectal Disease</i> , 2020, 35, 705-717. | 1.0 | 14 |
| 275 | Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 454-464. | 3.7 | 76 |
| 276 | Therapeutic resolution of focal, predominantly anastomotic Crohn's disease strictures using removable stents: outcomes from a single-center case series in the United Kingdom. <i>Gastrointestinal Endoscopy</i> , 2020, 92, 344-352. | 0.5 | 25 |
| 277 | A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn's Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 48-48. | 0.1 | 8 |
| 278 | Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost-effectiveness analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2397-2407. | 1.4 | 10 |
| 279 | Pharmacoeconomical Impacts of Crohn's Disease. , 0, , . | | 0 |
| 280 | Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study. <i>Health Technology Assessment</i> , 2021, 25, 1-138. | 1.3 | 2 |
| 281 | Crohn's disease: a population-based study of surgery in the age of biological therapy. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2419-2426. | 1.0 | 21 |
| 282 | Stromal Cells Underlining the Paths From Autoimmunity, Inflammation to Cancer With Roles Beyond Structural and Nutritional Support. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 658984. | 1.8 | 8 |
| 283 | Long-term Disease Course of Crohn's Disease: Changes in Disease Location, Phenotype, Activities, and Predictive Factors. <i>Gut and Liver</i> , 2022, 16, 157-170. | 1.4 | 8 |
| 284 | The clinical course of Crohn's disease in a Danish population-based inception cohort with more than 50 years of follow-up, 1962-2017. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 73-82. | 1.9 | 11 |
| 285 | Timing of surgery for enterovesical fistula in Crohn's disease: decision analysis using a time-dependent compartment model. <i>Inflammatory Bowel Diseases</i> , 2000, 6, 280-5. | 0.9 | 7 |
| 287 | The New Economic Reality in the World of IBD. , 2011, , 295-313. | | 1 |
| 288 | The Burden of Cost in Inflammatory Bowel Disease: A Medical Economic Perspective and the Future of Value-Based Care. <i>Current Gastroenterology Reports</i> , 2020, 22, 6. | 1.1 | 26 |
| 289 | Crohn's Disease: Current Pathogenetic Paradigms. , 2005, , 1265-1285. | | 4 |
| 291 | Management of Crohn's disease in adults. <i>American Journal of Gastroenterology</i> , 2001, 96, 635-643. | 0.2 | 258 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 292 | Description and Prediction of the Development of Metabolic Syndrome: A Longitudinal Analysis Using a Markov Model Approach. PLoS ONE, 2013, 8, e67436. | 1.1 | 21 |
| 293 | A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. ClinicoEconomics and Outcomes Research, 2014, 6, 431. | 0.7 | 13 |
| 294 | Anti-TNF and Crohns Disease: When Should We Stop?. Current Drug Targets, 2010, 11, 148-151. | 1.0 | 14 |
| 295 | Immunomodulators: Friends or Enemies in Surgery for Crohn's Disease?. Current Drug Targets, 2019, 20, 1384-1398. | 1.0 | 4 |
| 296 | A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF- α) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technology Assessment, 2011, 15, 1-244. | 1.3 | 105 |
| 297 | Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF- α) inhibitors [LISA-TRACKER [®] enzyme-linked immunosorbent assay (ELISA) kits, TNF- α -Blocker ELISA kits and Promonitor [®] ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling. Health Technology Assessment, 2016, 20, 1-288. | 1.3 | 27 |
| 298 | Role of conventional therapies in the era of biological treatment in Crohn's disease. World Journal of Gastroenterology, 2011, 17, 1797. | 1.4 | 11 |
| 299 | Crucial steps in the natural history of inflammatory bowel disease. World Journal of Gastroenterology, 2012, 18, 3790. | 1.4 | 94 |
| 300 | Impact of medical therapy on patients with Crohn's disease requiring surgical resection. World Journal of Gastroenterology, 2014, 20, 11808. | 1.4 | 7 |
| 301 | Cost-effectiveness of Crohn's disease post-operative care. World Journal of Gastroenterology, 2016, 22, 3860. | 1.4 | 9 |
| 302 | Early surgery in Crohn's disease a benefit in selected cases. World Journal of Gastrointestinal Surgery, 2016, 8, 492. | 0.8 | 29 |
| 303 | Clinical features and complications of Crohn's disease. , 2003, , 291-304. | | 0 |
| 304 | Pharmacoeconomics and inflammatory bowel disease. , 2003, , 471-480. | | 0 |
| 305 | Clinical Presentation. , 2010, , 43-51. | | 0 |
| 306 | Histoire naturelle de la maladie de Crohn. , 2011, , 105-114. | | 0 |
| 308 | What If I Do Not Get Myself Treated for Crohn's Disease? Natural History of Crohn's Disease. , 2015, , 35-39. | | 0 |
| 309 | Unusual Cause of Colonic Obstruction: A Case Report. Gastroenterology & Hepatology (Bartlesville,) Tj ETQq0 0 0 rgBT /Overlock 10 TF 5 | 0.0 | 0 |
| 310 | The changing landscape of surgery for Crohn's disease. Seminars in Colon and Rectal Surgery, 2020, 31, 100740. | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 311 | How do I use steroids in Crohn's disease?. , 0, , 111-119. | | 0 |
| 312 | Predicting the natural history of inflammatory bowel disease. , 0, , 63-69. | | 0 |
| 313 | Indications for use of infliximab in inflammatory bowel disease. , 0, , 165-182. | | 0 |
| 314 | Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2022, 28, 337-349. | 0.9 | 20 |
| 317 | Patients With Stricturing or Penetrating Crohn's Disease Phenotypes Report High Disease Burden and Treatment Needs. Inflammatory Bowel Diseases, 2023, 29, 914-922. | 0.9 | 2 |
| 318 | Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment. Inflammatory Bowel Diseases, 2023, 29, 898-913. | 0.9 | 2 |
| 319 | Mobile Apps for the Management of Gastrointestinal Diseases: Systematic Search and Evaluation Within App Stores. Journal of Medical Internet Research, 2022, 24, e37497. | 2.1 | 3 |
| 320 | Disease course and treatment outcomes of Crohn's disease patients with early or late surgery – A Danish nationwide cohort study from 1997 to 2015. Digestive and Liver Disease, 2023, 55, 872-879. | 0.4 | 3 |
| 322 | Molecular Basis of Intestinal Fibrosis in Inflammatory Bowel Disease. Inflammatory Intestinal Diseases, 2022, 7, 119-127. | 0.8 | 3 |